Genscript Biotech Corporation
GNNSF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $518,773 | $33,115 | $561,371 | $448,711 |
| % Growth | 1,466.6% | -94.1% | 25.1% | – |
| Cost of Goods Sold | $198,142 | $67,976 | $254,385 | $213,948 |
| Gross Profit | $320,631 | -$34,861 | $306,986 | $234,763 |
| % Margin | 61.8% | -105.3% | 54.7% | 52.3% |
| R&D Expenses | $31,321 | -$182,851 | $236,640 | $225,744 |
| G&A Expenses | $63,124 | -$5,798 | $120,173 | $106,926 |
| SG&A Expenses | $110,216 | -$18,878 | $221,374 | $202,052 |
| Sales & Mktg Exp. | $47,509 | -$9,217 | $97,338 | $92,894 |
| Other Operating Expenses | $0 | $6,814 | -$256 | -$20,710 |
| Operating Expenses | $141,537 | -$194,915 | $457,758 | $407,086 |
| Operating Income | $179,094 | $173,486 | -$150,772 | -$172,323 |
| % Margin | 34.5% | 523.9% | -26.9% | -38.4% |
| Other Income/Exp. Net | -$179,213 | $0 | -$54,816 | $65,880 |
| Pre-Tax Income | -$119 | $34,791 | -$205,588 | -$105,288 |
| Tax Expense | $24,428 | -$7,066 | $10,043 | $3,041 |
| Net Income | -$25,462 | $3,136,992 | -$175,115 | -$1,898 |
| % Margin | -4.9% | 9,473% | -31.2% | -0.4% |
| EPS | -0.012 | 1.48 | -0.083 | -0.001 |
| % Growth | -100.8% | 1,889.6% | -9,088.9% | – |
| EPS Diluted | -0.012 | 1.44 | -0.083 | -0.001 |
| Weighted Avg Shares Out | 1,179,561 | 2,121,285 | 2,116,603 | 2,098,592 |
| Weighted Avg Shares Out Dil | 2,156,075 | 2,178,302 | 2,116,588 | 2,098,592 |
| Supplemental Information | – | – | – | – |
| Interest Income | $9,838 | $58,757 | $87,651 | $47,323 |
| Interest Expense | $9,132 | $20,933 | $28,965 | $15,079 |
| Depreciation & Amortization | $29,835 | $27,919 | $32,835 | $38,525 |
| EBITDA | $208,929 | $187,973 | -$117,937 | -$51,699 |
| % Margin | 40.3% | 567.6% | -21% | -11.5% |